Statin Use and lowering of Cholesterol may reduce Breast Cancer Mortality

A recent groundbreaking study provides insights into the complex relationship between statin use, cholesterol levels, and breast cancer mortality, highlighting the potential benefits of post-diagnostic statin use, especially when accompanied by a decrease in cholesterol levels. The study results were published in the journal JAMA Network Open. 

Breast cancer (BC) remains a significant global health concern, and ongoing research endeavors continually seek to elucidate factors influencing BC mortality. A recent cohort study conducted in Finland between 1995 and 2013 delves into the intricate relationship between statin use, serum cholesterol levels, and breast cancer outcomes. The study, encompassing 13,378 female patients with invasive BC, aimed to discern the impact of statins on BC mortality while considering the crucial variable of cholesterol levels.

The findings of the study shed light on several noteworthy aspects. Post-diagnostic statin use emerged as a pivotal factor associated with a reduction in BC mortality compared to nonuse. This observation suggests that statins, commonly prescribed for cholesterol management, may confer an additional benefit by mitigating the risk of BC-related deaths. The study's duration, spanning from BC diagnosis to December 31, 2015, provided a median follow-up of 4.5 years, during which 16.4% of patients succumbed, with 7.0% attributed to BC.

An intriguing facet of the research is the nuanced role of cholesterol levels in mediating the association between statin use and BC mortality. Participants experiencing a decrease in cholesterol levels following statin initiation exhibited a robust risk reduction in BC mortality. In contrast, those whose cholesterol levels remained unchanged did not manifest a statistically significant risk reduction. 

The study's stratification based on estrogen receptor status yielded another compelling insight. Statin users with estrogen receptor–positive tumors exhibited a notable reduction in BC mortality. 

Contrary to post-diagnostic statin use, prediagnostic statin use emerged as a risk factor for BC death, even after adjusting for total cholesterol levels. 

Beyond its implications for BC mortality, the study extended its purview to overall mortality. Statin users demonstrated lower overall mortality compared to nonusers when adjusted for serum cholesterol levels. 

In conclusion, this comprehensive cohort study underscores the multifaceted interplay between statin use, cholesterol levels, and BC mortality. The post-diagnostic use of statins emerges as a potential ally in reducing BC-related deaths, particularly when accompanied by favorable changes in cholesterol levels. The nuanced findings, including subtype-specific effects and temporal considerations, underscore the complexity of this relationship, offering valuable insights for refining treatment strategies and shaping future research endeavors in the realm of breast cancer therapeutics.

Further reading: Murto MO, Simolin N, Arponen O, et al. Statin Use, Cholesterol Level, and Mortality Among Females With Breast Cancer. JAMA Netw Open. 2023;6(11):e2343861. doi:10.1001/jamanetworkopen.2023.43861